Characterisation of genome-wide PLZF/RARA target genes

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Spicuglia, Salvatore ^a,b,c   Vincent Fabert, Christelle ^b,d   Benoukraf, Touati ^a,b,c,h   Tibéri, Guillaume ^b,d   Saurin, Andrew J ^c,e   Zacarias Cabeza, Joaquin ^a,b,c   Grimwade, David ^f   Mills, Ken ^g   Calmels, Boris ^b,d   Bertucci, François ^b,d   Sieweke, Michael ^a,b,c   Ferrier, Pierre ^a,b,c   Duprez, Estelle ^a,b,c,d  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSERM   (France)

^c CNRS   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e AIX MARSEILLE UNIVERSITÉ   (France)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HYBRID PROTEIN; PLZF RARA FUSION PROTEIN; PROMYELOCYTIC LEUKEMIA ZINC FINGER PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; HISTONE; KRUPPEL LIKE FACTOR; ONCOPROTEIN; PLZF RARALPHA FUSION PROTEIN, HUMAN; PLZF-RARALPHA FUSION PROTEIN, HUMAN; ZBTB16 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; CELL STRAIN U937; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REPRESSION; GENOME; HISTONE MODIFICATION; HUMAN; HUMAN CELL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; ACETYLATION; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; METABOLISM; METHODOLOGY; METHYLATION; PATHOLOGY; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLATION; BINDING SITES; CHROMATIN IMMUNOPRECIPITATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENOME-WIDE ASSOCIATION STUDY; HISTONES; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKEMIA, PROMYELOCYTIC, ACUTE; METHYLATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; U937 CELLS;

EID: 80052948249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024176     Document Type: Article

References (41)

1. Scaglioni PP, Pandolfi PP, (2007) The theory of APL revisited. Curr Top Microbiol Immunol 313: 85-100.
2. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, et al. (2008) Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 111: 2887-2895.
3. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, et al. (2010) PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 17: 173-185.
4. Wang K, Wang P, Shi J, Zhu X, He M, et al. (2010) PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 17: 186-197.
5. Salomoni P, Pandolfi PP, (2000) Transcriptional regulation of cellular transformation. Nat Med 6: 742-744.
6. Kwok C, Zeisig BB, Dong S, So CW, (2006) Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell 9: 95-108.
7. Sternsdorf T, Phan VT, Maunakea ML, Ocampo CB, Sohal J, et al. (2006) Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell 9: 81-94.
8. Zhou J, Peres L, Honore N, Nasr R, Zhu J, et al. (2006) Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc Natl Acad Sci U S A 103: 9238-9243.
9. Hauksdottir H, Privalsky ML, (2001) DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth Differ 12: 85-98.
10. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, et al. (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18: 88-98.
11. Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, et al. (2007) RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 12: 23-35.
12. Grimwade D, Mistry AR, Solomon E, Guidez F, (2010) Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res 145: 219-235.
13. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, et al. (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85: 1083-1094.
14. Petrie K, Zelent A, Waxman S, (2009) Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 16: 84-91.
15. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, et al. (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818.
16. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, et al. (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co- repressors determine differential responses to RA in APL. Nat Genet 18: 126-135.
17. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, et al. (2009) The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 23: 1195-1206.
18. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, et al. (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814.
19. Guidez F, Parks S, Wong H, Jovanovic JV, Mays A, et al. (2007) RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad Sci U S A 104: 18694-18699.
20. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, et al. (1997) Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol 17: 4859-4869.
21. Benoukraf T, Cauchy P, Fenouil R, Jeanniard A, Koch F, et al. (2009) CoCAS: a ChIP-on-chip analysis suite. Bioinformatics 25: 954-955.
22. Barna M, Merghoub T, Costoya JA, Ruggero D, Branford M, et al. (2002) Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Dev Cell 3: 499-510.
23. Moog-Lutz C, Peterson EJ, Lutz PG, Eliason S, Cave-Riant F, et al. (2001) PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cells. J Biol Chem 276: 22375-22381.
24. Park DJ, Vuong PT, de Vos S, Douer D, Koeffler HP, (2003) Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood 102: 3727-3736.
25. Guibal FC, Moog-Lutz C, Smolewski P, Di Gioia Y, Darzynkiewicz Z, et al. (2002) ASB-2 inhibits growth and promotes commitment in myeloid leukemia cells. J Biol Chem 277: 218-224.
26. Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, et al. (2009) Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 114: 5499-5511.
27. Paietta E, (2003) Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16: 369-385.
28. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, et al. (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116: 2122-2126.
29. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, et al. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28: 3636-3643.
30. Yuki Y, Imoto I, Imaizumi M, Hibi S, Kaneko Y, et al. (2004) Identification of a novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13). Cancer Sci 95: 503-507.
31. O'Neil J, Look AT, (2007) Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 26: 6838-6849.
32. Lin HK, Bergmann S, Pandolfi PP, (2004) Cytoplasmic PML function in TGF-beta signalling. Nature 431: 205-211.
33. Lin HK, Bergmann S, Pandolfi PP, (2005) Deregulated TGF-beta signaling in leukemogenesis. Oncogene 24: 5693-5700.
34. Xu S, Furukawa T, Kanai N, Sunamura M, Horii A, (2005) Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet 50: 159-167.
35. Okudela K, Yazawa T, Woo T, Sakaeda M, Ishii J, et al. (2009) Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol 175: 867-881.
36. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, et al. (2007) Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11: 513-525.
37. Kamashev D, Vitoux D, de Thé H, (2004) PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199: 1163-1174.
38. Delacroix L, Moutier E, Altobelli G, Legras S, Poch O, et al. (2009) Cell-specific interaction of retinoic acid receptors with target genes in mouse embryonic fibroblasts and embryonic stem cells. Mol Cell Biol.
39. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
40. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
41. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.